Non-classical hormones from the fibroblast growth factor family

• Published in: Problemy ėndokrinologii 2024-11, Vol.70 (5), p.23-33
• Main Authors: Gronskaia, S. A., Rusyaeva, N. V., Belaya, Zh. E., Melnichenko, G. A.
• Format: Article
• Language: eng ; rus
• ISSN: 0375-9660; 2308-1430
• DOI: 10.14341/probl13441

Fibroblast growth factors (FGFs) are a group of signaling molecules named for their ability to promote the growth and proliferation of fibroblasts and various other cell types. Typically, FGFs exert their effects locally by binding to receptors within the tissues where they are synthesized. However, certain members of this family, such as FGF 19, FGF 21, and FGF 23, diverge from this pattern. Following synthesis, these FGFs enter the bloodstream and act on distant organs and tissues by binding to their receptors and associated cofactors, thereby classified as non-classical hormones within the FGF family. The biological functions of FGFs are diverse and contingent upon the specific receptors and cofactors involved in their signaling pathways. For instance, FGF 19 and FGF 21 play crucial roles in regulating glucose and lipid metabolism, whereas FGF 23 primarily influences phosphorus metabolism. Given their varied roles, FGFs present promising targets for therapeutic interventions and drug development. This review aims to consolidate current understanding of FGF family hormones, elucidating their biological impacts and exploring their potential applications as therapeutic targets.